Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperthyroidism14.11.01.011; 05.02.02.0010.014227%
Hypertonia15.05.04.007; 17.05.02.0010.017783%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypokinesia17.01.02.009--Not Available
Hypotension24.06.03.0020.199175%
Hypothyroidism14.11.01.012; 05.02.03.0010.103144%
Hypoxia22.02.02.0030.022763%
Immune system disorder10.02.01.001--Not Available
Incontinence07.01.06.011; 20.02.02.004; 17.05.01.0060.007113%Not Available
Injection site extravasation12.07.03.002; 08.02.03.0020.034856%Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Lacrimation increased06.08.02.0040.024897%
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.046237%
Laryngospasm22.04.02.0020.007113%
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.0040.021340%Not Available
Lip swelling23.04.01.007; 07.05.04.005; 10.01.05.0050.029876%Not Available
Loss of consciousness17.02.04.0040.124484%Not Available
Macule23.03.03.0370.007113%Not Available
Malaise08.01.01.003--
Metabolic acidosis14.01.01.0030.014227%Not Available
Micturition urgency20.02.02.0060.007113%
Migraine24.03.05.003; 17.14.02.001--Not Available
Muscle spasms15.05.03.004--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nasal congestion22.04.04.0010.029876%
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene